Advancements in Minimal Residual Disease (MRD) Diagnostics set the Stage for Novel Clinical Trial
Time: 2:30 pm
day: Day Two Track B PM
Details:
• Overview of the unmet need in early line large B-cell lymphoma (LBCL) patients
• MRD status as prognostic indicator of patient outcomes
• Novel trial utilizing innovative biomarker for patient selection
